Last reviewed · How we verify
NCT05614765
Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment
trial testing Statin+Ezetimibe compound in Dyslipidemias in 18,000 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2023
Quick facts
| Lead sponsor | Daewoong Pharmaceutical Co. LTD. |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 18,000 |
| Start date | 8 July 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Statin+Ezetimibe compound — full drug profile →
Conditions studied
- Dyslipidemias — all drugs for Dyslipidemias →
Sponsor
Daewoong Pharmaceutical Co. LTD. — full company profile →
Who can join
19 and older, any sex, with Dyslipidemias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a large-scale, prospective, multi-site, and non-interventional observational study to observe the change and safety of dyslipidemia management status when administering statin+etimib complex drugs in patients with dyslipidemia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05614765
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dyslipidemias
Currently open trials in the same condition.
- NCT07308314 — Taining Golden Lake Comprehensive Chronic Disease Management Initiative · recruiting
- NCT06526273 — PILI 'Āina Household · NA · recruiting
- NCT06797401 — Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia · Phase 2 · recruiting
- NCT06380322 — Military Health and Nutrition Examination Study · recruiting
- NCT06183307 — Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia · NA · recruiting
Other Daewoong Pharmaceutical Co. LTD. trials
Trials by the same sponsor.
- NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
- NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
- NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
- NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
- NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05614765 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
- Last refreshed: 24 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05614765.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing